Introduction
============

Psoriasis is a common immune-mediated skin disease. The prevalence of psoriasis in adults ranges between 0.91 and 8.5% worldwide and the incidence of psoriasis is higher in adults than in children ([@b1-etm-0-0-6859]). Psoriasis is characterized by symptoms of plaque, pustular and other skin lesions. Chronic plaque psoriasis accounts for 90% of all psoriasis cases ([@b2-etm-0-0-6859],[@b3-etm-0-0-6859]).

A number of biological therapies are used to treat moderate to severe psoriasis, including etanercept, briakinumab, ustekinumab, adalimumab and infliximab ([@b4-etm-0-0-6859]--[@b8-etm-0-0-6859]). Etanercept, adalimumab and infliximab are monoclonal antibodies against tumor necrosis factor (TNF), which function by neutralizing the biological activity of TNF for treating the TNF-mediated inflammation ([@b5-etm-0-0-6859],[@b9-etm-0-0-6859]). By contrast, ustekinumab and briakinumab are human monoclonal antibodies against interleukin (IL)-12/23p40 ([@b8-etm-0-0-6859]). These biological therapies are used to treat psoriasis and improved clinical outcomes have been observed. However, the efficacy of these therapies has been not systematically reviewed.

In the present study, a network meta-analysis was performed to review and compare the efficacy of these aforementioned biological therapies of psoriasis. The Psoriasis Area and Severity Index (PASI) response ([@b10-etm-0-0-6859]) was used as an indicator for assessing the effect of treatment on the severity of psoriasis. PASI 50, PASI 75 and PASI 90 responses for the therapies were systematically assessed. The pooled results provide further information on selecting the most suitable treatments for moderate to severe psoriasis.

Materials and methods
=====================

### Data sources

The PubMed ([www.ncbi.nlm.nih.gov/pubmed](www.ncbi.nlm.nih.gov/pubmed)) and Embase ([www.elsevier.com/solutions/embase-biomedical-research](www.elsevier.com/solutions/embase-biomedical-research)) databases were systematically searched in order to select relevant studies up to February 2015. The search terms included the following: Psoriasis, methotrexate (MTX), cyclosporin A (CSA), ustekinumab, etanercept, infliximab, briakinumab and adalimumab.

### Inclusion and exclusion criteria

Studies with the following characteristics were included in the current meta-analysis: i) Randomized controlled trials (RCTs) reporting the treatment of moderate to severe psoriasis with the aforementioned drugs. Moderate to severe psoriasis is defined as body surface area \>10 or psoriasis area and severity index \>10 and dermatology life quality index \>10 ([@b11-etm-0-0-6859]); ii) studies including the adults as participants; and iii) studies reporting the PASI response rate (50, 75 and 90%). Any reviews, case reports and letters were excluded from the meta-analysis. Any studies investigating patients with mild psoriasis and those written in a language other than English were also excluded.

### Data extraction and quality assessment

Two reviewers independently extracted the following data: The name of the first author, publication year, sample size, intervention, demographic characteristics of the included patients and PASI response rate. The controversies were discussed with a third reviewer to reach consensus. The methodological quality of the included studies was evaluated by the Cochrane Collaboration Risk of Bias Tool ([@b12-etm-0-0-6859]).

### Statistical analysis

All analyses were performed using the ADDIS software version 1.16.5 (Drug Information and Monitoring Systems, Groningen, The Netherlands). Odds ratios (ORs) and their 95% confidence intervals (CIs) were pooled. The network analysis performed was based on the Bayesian framework. Data were evaluated by Markov chain Monte Carlo methods and all analyses were performed using the random effects model. The consistency of the RCTs was assessed by Node-splitting analysis, and the consistency model was used if P\>0.05. Otherwise, the inconsistency model was used to pool the odd ratios ([@b13-etm-0-0-6859]).

Results
=======

### Study selection

As presented in [Fig. 1](#f1-etm-0-0-6859){ref-type="fig"}, a total of 897 studies were identified from PubMed and 917 studies from Embase by the initial search. Subsequent to excluding any duplicates, 1,113 studies remained. A total of 831 irrelevant studies were excluded by reviewing the titles and abstracts. In addition, 249 studies that did not meet the inclusion criteria were excluded. Finally, 33 RCTs were included in the present study ([@b4-etm-0-0-6859]--[@b9-etm-0-0-6859],[@b14-etm-0-0-6859]--[@b40-etm-0-0-6859]).

### Characteristics of the included studies

As presented in [Table I](#tI-etm-0-0-6859){ref-type="table"}, the demographic characteristics, including age, sex and weight of the patients in the included studies were similar. Included RCTs were published between 1994 and 2015. The mean duration of psoriasis of the included patients ranged between 11.1 and 21.5 years. Quality assessment demonstrated that the quality of the included RCTs was relatively high. With respect to random sequence generation (selection bias), a number of studies were assessed as having an unclear risk of bias. With regards to blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias) and incomplete outcome data (attrition bias), a small proportion of studies were assessed as having high risk of bias ([Fig. 2](#f2-etm-0-0-6859){ref-type="fig"}) and were excluded from the current study. However, the studies by Laburte *et al* ([@b25-etm-0-0-6859]) and Cassano *et al* ([@b15-etm-0-0-6859]) were not excluded as they met with the inclusion criteria despite having quite a poor rating.

### Network meta-analysis

Based on the results of node-splitting analysis ([Table II](#tII-etm-0-0-6859){ref-type="table"}), the effect sizes were pooled using an inconsistency model. Regarding the PASI 75 response rate, infliximab (5 mg) was the most effective option for the treatment of moderate to severe psoriasis ([Table III](#tIII-etm-0-0-6859){ref-type="table"} and [Fig. 3](#f3-etm-0-0-6859){ref-type="fig"}). The pooled results of the PASI 50 response rate demonstrated that infliximab (5 mg) and ustekinumab (90 mg) may be superior to other drugs for treating moderate to severe psoriasis ([Table IV](#tIV-etm-0-0-6859){ref-type="table"}). In addition, regarding the PASI 90 response rate, treatment with infliximab (5 mg), ustekinumab (90 mg) and briakinumab (weeks 0 and 4, 200 mg; week 8, 100 mg) indicated improved results compared with other agents ([Table V](#tV-etm-0-0-6859){ref-type="table"}). Finally, the drugs can be ranked in the following order according to their efficacy, defined as their PASI 90 response rate: Briakinumab \> ustekinumab (90 mg) \> infliximab (5 mg)\> ustekinumab (45 mg) \> adalimumab \> infliximab (3 mg)\> etanercept (50 mg BIW) \> CSA (5 mg) \> etanercept (25 mg BIW) \> MTX \> etanercept (25 mg QW) \> placebo ([Table VI](#tVI-etm-0-0-6859){ref-type="table"}). The odds ratio value of infliximab (5 mg) compared with the other drugs was \>1, therefore, infliximab (5 mg) was regarded as the best treatment agent, although it ranked as third in terms of efficacy.

Discussion
==========

In the present study, a network meta-analysis was performed to systematically review and compare the efficacy of seven drugs used at different doses for treating moderate to severe psoriasis. Based on the results of the network analysis, infliximab (5 mg) may be an appropriate option to treat moderate to severe psoriasis.

Psoriasis has been reported to be associated with a high concentration of TNF-α ([@b41-etm-0-0-6859]) and infliximab treatment can neutralize the biological activity of TNF-α ([@b42-etm-0-0-6859]). However, the role of the TNF-α in the pathogenesis of psoriasis remains unclear. Previous studies have reported that TNF-α may serve an important role in the upstream of the inflammatory responses of psoriasis ([@b43-etm-0-0-6859],[@b44-etm-0-0-6859]). An *in vitro* study determined that infliximab was able to inhibit the activation of skin-homing T cells and impair the antigen-presenting capacity of immature dendritic cells in psoriasis patients ([@b43-etm-0-0-6859]). However, another TNF-α inhibitor, etanercept, has been found to be effective in the treatment of psoriasis by reducing the Th17 cell products, as well as the production of IL-17, IL-22, IL-23 and inducible NO synthase from dendritic cells ([@b44-etm-0-0-6859]). Thus, it has been suggested that the infliximab may serve a different role with other treatments on moderate to severe psoriasis.

Although the present meta-analysis indicated that infliximab treatment had a high PASI score, a higher percentage of adverse events were observed in infliximab-treated patients compared with those in the placebo group ([@b18-etm-0-0-6859]), indicating that infliximab treatment induces adverse effects. In addition, infliximab treatment increases the incidence of infusion reactions ([@b45-etm-0-0-6859]). However, these outcomes were not considered to be important due to the small sample size of each study or the fact that the data were unavailable. Thus, the therapeutic effect of the infliximab should be systematically assessed in further studies. Besides, the dosage and treatment duration of infliximab should be optimized according to the disease severity of psoriasis.

In the present study, briakinumab and ustekinumab (90 mg) treatments were superior to other treatments for PASI 90 response. Thus, anti-IL-12/23 monoclonal antibodies appear to be more appropriate compared with anti-TNF-α treatment for treating moderate to severe psoriasis. However, briakinumab and ustekinumab showed no significantly improved therapeutic effect in PASI 75 and PASI 50 responses when compared with the anti-TNF-α treatments. In addition, the long-term safety profile, including severe infections and cardiac disorders, should be evaluated in further studies with large sample sizes and strict study design.

To the best of our knowledge, the present study is the first network meta-analysis for evaluating the efficacy of various treatments for moderate to severe psoriasis. The current results may provide information for clinician and patients on the selection of the suitable treatment for moderate to severe psoriasis. However, there were also several limitations in the present meta-analysis. Firstly, due to unavailable data in certain included studies, confounding variables could not be adjusted and subgroup analysis was not performed to reduce the effect of the confounding variables. Secondly, due to unknown bias, the network analyses of PASI 75 and PASI 50 responses were performed using an inconsistency model. Finally, the results of the network meta-analysis should be pooled only by a random effects model. Thus, the pooled results may be conservative and certain borderline significant effects may have been ignored ([@b46-etm-0-0-6859]).

In conclusion, the present meta-analysis results suggested that infliximab (5 mg) may be a superior option compared with other drugs for treating moderate to severe psoriasis due to the relatively high PASI scores of patients. However, despite the high PASI 90 responses, the efficacy of ustekinumab (90 mg) and briakinumab were also high and therefore should be investigated in further studies.
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###### 

Characteristics of the included studies.

  First author           Year   Follow-up      Treatment              N      Age (years)         M/F       Weight (kg)         Duration of psoriasis (years)   PASI score         PASI 75   PASI 50   PASI 90   (Refs.)
  ---------------------- ------ -------------- ---------------------- ------ ------------------- --------- ------------------- ------------------------------- ------------------ --------- --------- --------- ------------------------
  Laburte et al          1994   0.2--18.3      CSA 5 mg               132      40.7±12.3         90/42     72.9±3.4            17.7±11.1                       25.1±8.0           117       NA        NA        ([@b25-etm-0-0-6859])
                                months         CSA 2.5 mg             119      42.0±12.6         86/33       77.4±15.5         18.4±11.1                       24.9±7.0             57      NA        NA        
  Gordon et al           2006   60 weeks       Adalimumab               45   46 (20--71)         32/13     93 (63--159)        21 (1.3--57.9)                  16.7 (5.4--39.0)     24      NA        NA        \(17\)
                                               Placebo                  52   43 (20--70)         34/18     94(50--147)         19 (1.0--39.9)                  16.0(5.5--40.4)      2       NA        NA        
  Menter et al           2008   16 weeks       Adalimumab             814      44.1±13.2         546/268     92.3±23.0           18.1±11.91                      19.0±7.08        578       NA        366         ([@b2-etm-0-0-6859])
                                               Placebo                398      45.4±13.4         257/141     94.1±23.0           18.4±11.94                      18.8±7.09          28      NA          8       
  Asahina et al          2010   24 weeks       Adalimumab               38     47.8±12.81        32/6        69.7±15.48        14.2±9.29                       25.44±8.98           24      31          15        ([@b5-etm-0-0-6859])
                                               Placebo                  46     43.9±10.75        41/5        71.3±15.28        15.5±8.83                       29.10±11.77          2         9         0       
  Revicki et al          2008   16 weeks       Adalimumab             108      42.8±12.3         37/71     NA                  17.6±10.0                       20.1±7.4             86      95          55      ([@b34-etm-0-0-6859])
                                               MTX                    110      41.9±11.9         36/74     NA                  19.0±10.3                       19.5±7.4             66      68          15      
                                               Placebo                  53     40.7±11.4         18/35     NA                  18.9±8.7                        19.2±6.9             10      16          6       
  Leonardi et al         2003   12 weeks       Etanercept 50 mg BIW   164    44.8±0.8            107/57    NA                  18.6±0.9                        18.4±0.7             81      121         36      ([@b27-etm-0-0-6859])
                                               Etanercept 25 mg BIW   162    45.4±1.0            109/53    NA                  18.5±0.9                        18.5±0.7             55      94          19      
                                               Etanercept 25 mg QW    160    44.4±0.9            118/42    NA                  19.3±0.9                        18.2±0.7             23      65          5       
                                               Placebo                166    45.6±1.0            105/61    NA                  18.4±0.9                        18.3±0.6             6       24          1       
  Papp et al             2005   12 weeks       Etanercept 50 mg BIW   194    44.5 (21.0--80.0)   130/64    NA                  18.1 (0.8--60.5)                16.1 (7.0--57.3)     96      150       40        ([@b32-etm-0-0-6859])
                                               Etanercept 25 mg BIW   196    46.0 (20.0--87.0)   128/68    NA                  21.5 (0.8--64.6)                16.9 (4.0--51.2)     67      126       21        
                                               Placebo                193    44.0 (18.0--80.0)   124/69    NA                  17.5 (1.4--51.2)                16.0 (7.0--62.4)     6       18          1       
  Tyring et al           2006   12 weeks       Etanercept 50 mg BIW   311    45.8±12.8           203/108   NA                  20.1±12.3                       18.3±7.6           146       230         65      ([@b37-etm-0-0-6859])
                                               Placebo                307      45.6±12.1         216/91    NA                  19.7±11.4                       18.1±7.4             15      43          3       
  van de Kerkhof et al   2008   12 weeks       Etanercept 25 mg BIW     96     45.9±12.8         59/36       83.4±16.0         19.3±11.3                       21.4±9.3             36      66          13      ([@b38-etm-0-0-6859])
                                               Placebo                  46     43.6±12.6         25/21       79.1±20.2         17.3±8.2                        21.0±8.7             1         4         1       
  Cassano et al          2010   12 weeks       Etanercept 50 mg BIW     36   NA                  NA        NA                  NA                              NA                   19      33        NA        ([@b40-etm-0-0-6859])
                                               Etanercept 100 mg QW     36   NA                  NA        NA                  NA                              NA                   13      27        NA        
  Strober et al          2011   12 weeks       Etanercept 50 mg BIW   139      45.2±14.8         85/54       96.9±24.9         15.2±12.1                       18.5±6.0           55        NA        19        ([@b8-etm-0-0-6859])
                                               Briakinumab            139      44.9±12.9         93/46       96.1±24.5         16.3±12.0                       19.4±7.9           112       NA        77        
                                               Placebo                72       45.0±13.9         46/26       92.9±25.2         15.5±11.7                       18.3±6.4           5         NA        3         
  Gottlieb et al         2011   12 weeks       Etanercept 50 mg BIW   141      43.1±12.5         98/43       94.5±20.4         17.0±12.7                       19.4±8.0           78        NA        32        ([@b19-etm-0-0-6859])
                                               Briakinumab            138      43.6±14.3         89/49       93.2±22.9         16.1±12.5                       18.4±7.2           113       NA        81        
                                               Placebo                68       44.0±13.6         47/21       96.5±27.2         19.1±13.2                       18.5±6.9           5         NA        1         
  Bagel et al            2012   12 weeks       Etanercept 50 mg BIW   62     39 (18.0--71.0)     29/33     30.2 (18.2--44.2)   17.5 (1--45)                    15.5 (8--46)       37        53        16        ([@b8-etm-0-0-6859])
                                               Placebo                62     42 (18.0--70.0)     26/36     30.2 (18.2--44.2)   11.9 (1--49)                    15.2 (10--41)      3         4         1         
  Gottlieb et al         2003   10 weeks       Infliximab 5 mg        99     44 (34, 53)         73/26     NA                  16 (10, 25)                     20 (14, 28)        87        96        47        ([@b20-etm-0-0-6859])
                                               Infliximab 3 mg        99     45 (37, 55)         70/29     NA                  18 (12, 24)                     20 (15, 26)        71        83        45        
                                               Placebo                51     45 (30, 52)         31/20     NA                  16 (6, 22)                      18 (15, 27)        3         11        1         
  Reich et al            2005   24 weeks       Infliximab 5 mg        301      42.6±11.7         207/94    NA                  19.1±11.0                       22.9±9.3           227       248       161       ([@b33-etm-0-0-6859])
                                               Placebo                77       43.8±12.6         61/16     NA                  17.3±11.1                       22.8±8.7           3         6         1         
  Menter et al           2007   14 weeks       Infliximab 5 mg        314      44.5±13.0         204/110     92.2±23.2         19.1±11.7                       20.4±7.5           193       252       113       ([@b29-etm-0-0-6859])
                                               Infliximab 3 mg        313      43.4±12.6         206/107     92.0±22.5         18.1±11.8                       20.1±7.9           149       213       75        
  Torii and Nakagawa     2010   14 weeks       Infliximab 5 mg        35       46.9±13.0         22/13       68.5±13.4         14.2±8.9                          31.9±12.8        25        29        17        ([@b35-etm-0-0-6859])
                                               Placebo                19       43.3±12.3         14/5      69.7±8.9            11.1±6.5                          33.1±15.6        2         2         1         
  Yang et al             2012   10 weeks       Infliximab 5 mg        84     39.4±12.3           60/24     68.2±9.2              16.0±10.8                     NA                 68        79        48        ([@b39-etm-0-0-6859])
                                               Placebo                45     40.1±11.1           35/10     67.4±9.9            16.0±8.9                        NA                 1         6         0         
  Barker et al           2011   26 weeks       Infliximab 5 mg        653      44.1 (±18--78)    438/215   84.5±18.6             18.8±11.6                     21.4±8.0           502       529       333       ([@b14-etm-0-0-6859])
                                               MTX                    215      41.9 (±18--69)    148/67    83.8±18.2             17.0±10.3                     21.1±7.6           66        103       32        
  Leonardi et al         2008   12 weeks       Ustekinumab 90 mg      256    46.2±11.3           173/83    93.8±23.9             19.6±11.1                     19.7±7.6           170       220       94        ([@b26-etm-0-0-6859])
                                               Ustekinumab 45 mg      255    44.8±12.5           175/80    93.7±23.8             19.7±11.7                     20.5±8.6           171       213       106       
                                               Placebo                255    44.8±11.3           183/72    94.2±23.5             20.4±11.7                     20.4±8.6           8         26        5         
  Papp et al             2008   12 weeks       Ustekinumab 90 mg      411    46.6±12.1           274/137   91.5±21.3             20.3±12.3                     20.1±7.5           311       367       209       ([@b31-etm-0-0-6859])
                                               Ustekinumab 45 mg      409    45.1±12.1           283/126   90.3±21.0             19.3±11.7                     19.4±6.8           273       342       173       
                                               Placebo                410    47.0±12.5           283/127   91.1±21.6           20.8±12.2                       19.4±7.5           15        41        3         
  Griffiths              2010   36 weeks       Ustekinumab 90 mg      247    NA                  NA        NA                  NA                              NA                 183       NA        111       ([@b21-etm-0-0-6859])
                                               Ustekinumab 45 mg      209    NA                  NA        NA                  NA                              NA                 142       NA        75        
                                               Etanercept 50 mg BIW   347    NA                  NA        NA                  NA                              NA                 198       NA        80        
  Tsai et al             2011   12 weeks       Ustekinumab 45 mg      61     40.9±12.7           50/11     73.1±12.7           11.9±7.5                          25.2±11.9        41        51        30        ([@b36-etm-0-0-6859])
                                               Placebo                60     40.4±10.1           53/7      74.6±13.0           13.9±7.3                        22.9±8.6           3         8         1         
  Igarashi et al         2012   12 weeks       Ustekinumab 45 mg      64     M: 45.0             53/11     73.2±15.4           15.8±8.2                          30.1±12.9        38        53        21        ([@b24-etm-0-0-6859])
                                               Ustekinumab 90 mg      62     M: 44.0             47/15     71.1±14.0             17.3±10.7                       28.7±11.2        42        52        27        
                                               Placebo                32     M: 49.0             26/6        71.2±10.9           16.0±11.2                       30.3±11.8        2         4         1         
  Heydendael et al       2003   17--52 weeks   CSA 2.5 mg             42     41.6±13.0           29/13     NA                  NA                              14.0±6.6           30        NA        NA        ([@b22-etm-0-0-6859])
                                               MTX                    43     38.3±12.4           28/15     NA                  NA                              13.4±3.6           26        NA        NA        
  Flytstrom et al        2008                  CSA 5 mg               31     45 (18--70)         27/4      87 (61--130)        NA                              15.5±6.3           18        27        9         ([@b16-etm-0-0-6859])
                                               MTX                    37     48 (23--78)         28/9      85 (56--132)        NA                              14.1±7.0           22        24        4         
  Ho et al               2010   6 months       MTX                    20     38.45 (21--68)      18/2      NA                  NA                              NA                 13        NA        0         ([@b23-etm-0-0-6859])
                                               Placebo                20     43.45 (27--61)      18/2      NA                  NA                              NA                 16        NA        5         
  Gottlieb et al         2003   24 weeks       Etanercept 25 mg BIW   57     48.2 (25--72)       33/24     Mean: 91.8          23±1.6                          17.8±1.1           17        40        6         ([@b20-etm-0-0-6859])
                                               Placebo                55     46.5 (18--77)       37/18     Mean: 90.7          20±1.7                          19.5±1.3           1         6         0         
  Cassano et al          2006   12 weeks       Etanercept 50 mg BIW   53     42.3 (18--73)       57/52     NA                  NA                              8.7 (5.4--11.6)    29        39        NA        ([@b15-etm-0-0-6859])
                                               Etanercept 100 mg QW   55                                   NA                  NA                                                 28        43        NA        
  Sterry et al           2010   12 weeks       Etanercept 50 mg BIW   379    46±11               243/136   NA                    19±12                           20±11            208       NA        NA        ([@b7-etm-0-0-6859])
                                               Etanercept 50 mg QW    373    47±11               230/143   NA                    19±11                           19±10            134       NA        NA        
  Antoni et al           2005   16 weeks       Infliximab 5 mg        52     45.7±11.1           30/22     NA                    19.4±11.6                       5.1±5.9          35        NA        NA        ([@b4-etm-0-0-6859])
                                               Placebo                52     45.2±9.7            30/22     NA                    16.9±10.9                       4.2±5.8          0         NA        NA        
  McInnes et al          2013   12 weeks       Ustekinumab 45 mg      205    48.0 (39.0--55.0)   106/99    NA                  12.0 (4.1--22.2)                7.1 (3.3--15.3)    83        NA        NA        ([@b28-etm-0-0-6859])
                                               Ustekinumab 90 mg      204    47.0 (38.5--54.0)   116/88    NA                  14.1 (5.4--22.4)                8.4 (4.8--14.7)    93        NA        NA        
                                               Placebo                206    48.0 (39.0--57.0)   108/98    NA                  13.1 (5.3--23.5)                8.8 (4.4--14.3)    16        NA        NA        
  Griffiths et al        2015   12 weeks       Etanercept 50 mg QW    371    46.9±11.4           229       NA                    18.6±11.4                     19.0±9.8           148       NA        NA        ([@b6-etm-0-0-6859])
                                               Etanercept 50 mg BIW   377    46.1±11.4           241       NA                    19.2±11.9                     19.8±10.7          226       NA        NA        

Data are presented as the mean ± standard deviation, or as the median (range). PASI, Psoriasis Area and Severity Index; MTX, methotrexate; CSA, cyclosporin A; BIW, twice weekly; QW, once weekly; M/F, male/female; NA, not available; Ref, study reference number; M, mean value.

###### 

Node-splitting analysis.

  Name                                           Direct effect          Indirect effect        Overall                P-value
  ---------------------------------------------- ---------------------- ---------------------- ---------------------- ---------
  PASI 75                                                                                                             
    Adalimumab, MTX                              −1.03 (−2.13, 0.09)    −0.13 (−1.44, 1.31)    −0.81 (−1.64, 0.10)    0.28
    CSA 2.5 mg, CSA 5 mg                         2.15 (1.15, 3.13)      −0.55 (−2.24, 1.08)    1.47 (0.44, 2.41)      0.01
    CSA 2.5 mg, MTX                              −0.51 (−1.71, 0.64)    2.24 (0.71, 3.77)      0.46 (−0.62, 1.48)     0.01
    CSA 5 mg, MTX                                0.02 (−1.18, 1.24)     −2.70 (−4.23, −1.12)   −1.01 (−2.06, 0.07)    0.01
    Etanercept 25 mg BIW, Etanercept 50 mg BIW   0.64 (−0.08, 1.35)     −0.05 (−1.03, 0.89)    0.41 (−0.27, 1.01)     0.23
    Etanercept 50 mg BIW, Placebo                −3.02 (−3.57, −2.49)   −3.18 (−4.11, −2.32)   −3.03 (−3.51, −2.58)   0.74
    Etanercept 50 mg BIW, Ustekinumab 45 mg      0.46 (−0.61, 1.51)     0.51 (−0.19, 1.18)     0.48 (−0.15, 1.08)     0.9
    Etanercept 50 mg BIW, Ustekinumab 90 mg      0.77 (−0.29, 1.80)     0.54 (−0.20, 1.20)     0.62 (−0.00, 1.23)     0.69
    Infliximab 3 mg, Placebo                     −3.86 (−5.56, −2.35)   −3.95 (−5.09, −2.86)   −3.95 (−4.95, −3.01)   0.94
    Infliximab 5 mg, MTX                         −2.01 (−3.06, −1.04)   −2.18 (−3.45, −0.84)   −2.08 (−2.86, −1.25)   0.83
    Infliximab 5 mg, Placebo                     −4.83 (−5.77, −4.02)   −4.65 (−6.16, −3.25)   −4.73 (−5.50, −4.08)   0.81
    MTX, Placebo                                 −2.53 (−3.72, −1.49)   −2.70 (−3.69, −1.78)   −2.66 (−3.50, −1.92)   0.81
    Placebo, Ustekinumab 45 mg                   3.54 (2.96, 4.11)      3.44 (2.39, 4.44)      3.52 (2.99, 4.02)      0.83
    Placebo, Ustekinumab 90 mg PASI 50           3.60 (2.97, 4.18)      3.83 (2.83, 4.83)      3.65 (3.11, 4.17)      0.65
  PASI 50                                                                                                             
    Adalimumab, MTX                              −1.51 (−2.41, −0.70)   0.04 (−1.06, 1.18)     −1.10 (−2.03, −0.21)   0.02
    Etanercept 25 mg BIW, Etanercept 50 mg BIW   0.64 (−0.05, 1.38)     0.73 (−0.20, 1.76)     0.61 (0.02, 1.21)      0.88
    Etanercept 50 mg BIW, Placebo                −3.13 (−3.66, −2.70)   −3.82 (−4.93, −2.73)   −3.22 (−3.78, −2.75)   0.24
    Infliximab 3 mg, Placebo                     −3.11 (−4.31, −1.87)   −2.93 (−4.01, −1.89)   −3.04 (−3.92, −2.25)   0.82
    Infliximab 5 mg, MTX                         −1.54 (−2.19, −0.88)   −3.08 (−4.17, −2.09)   −2.02 (−2.88, −1.37)   0.01
    Infliximab 5 mg, Placebo                     −4.45 (−5.18, −3.92)   −2.93 (−3.90, −1.90)   −4.13 (−4.79, −3.55)   0.01
    MTX, Placebo                                 −1.42 (−2.34, −0.45)   −2.57 (−3.39, −1.73)   −2.11 (−2.85, −1.31)   0.06
  PASI 90                                                                                                             
    Adalimumab, MTX                              −2.04 (−3.04, −0.99)   −0.49 (−1.91, 0.86)    −1.67 (−2.58, −0.81)   0.08
    Etanercept 25 mg BIW, Etanercept 50 mg BIW   0.86 (0.14, 1.62)      −0.03 (−1.47, 1.35)    0.75 (0.04, 1.39)      0.24
    Etanercept 50 mg BIW, Placebo                −3.15 (−3.90, −2.45)   −3.34 (−4.48, −2.42)   −3.16 (−3.78, −2.63)   0.76
    Etanercept 50 mg BIW, Ustekinumab 45 mg      0.63 (−0.36, 1.70)     0.99 (0.12, 1.83)      0.82 (0.19, 1.48)      0.53
    Etanercept 50 mg BIW, Ustekinumab 90 mg      1.00 (0.01, 2.02)      0.73 (−0.10, 1.59)     0.90 (0.22, 1.52)      0.61
    Infliximab 3 mg, Placebo                     −4.12 (−8.54, −2.14)   −3.54 (−4.91, −2.48)   −3.56 (−4.64, −2.64)   0.69
    Infliximab 5 mg, MTX                         −1.80 (−2.74, −0.87)   −2.98 (−4.73, −1.47)   −2.07 (−2.97, −1.38)   0.18
    Infliximab 5 mg, Placebo                     −4.46 (−6.00, −3.43)   −3.33 (−4.77, −2.10)   −3.93 (−4.80, −3.18)   0.2
    MTX, Placebo                                 −1.24 (−2.38, −0.25)   −2.30 (−3.43, −1.40)   −1.85 (−2.60, −1.07)   0.12
    Placebo, Ustekinumab 45 mg                   4.15 (3.45, 4.86)      3.78 (2.83, 4.68)      3.99 (3.37, 4.61)      0.37
    Placebo, Ustekinumab 90 mg                   3.99 (3.22, 4.77)      4.32 (3.40, 5.28)      4.07 (3.40, 4.70)      0.44

PASI, Psoriasis Area and Severity Index; MTX, methotrexate; CSA, cyclosporin A; BIW, twice weekly; QW, once weekly.

###### 

Network meta-analysis of PASI 75 response rate between drugs for treating psoriasis.

                                                 CSA            Etanercept       Infliximab                                   Ustekinumab                                                                                                   
  ------------- --------------- ---------------- -------------- ---------------- -------------- -------------- -------------- -------------- -------------- ---------------- ---------------- --------------- ------------- --------------- ---------------
  Adalimumab    --              2.25             0.31           1.50             0.37           0.43           0.10           0.55           0.25           1.39             3.04             0.39            0.03          0.91            1.04
                                (0.49,7.32)      (0.08,1.34)    (0.34,8.64)      (0.06,1.53)    (0.11,1.59)    (0.02,0.45)    (0.11,1.67)    (0.04,0.94)    (0.37,4.75)      (0.99,8.77)      (0.16,1.02)     (0.02,0.06)   (0.22,2.54)     (0.25,2.91)
  Briakinumab   0.44            --               0.14           0.67             0.16           0.20           0.04           0.23           0.11           0.62             1.37             0.18            0.01          0.40            0.46
                (0.14,2.03)                      (0.03,1.01)    (0.12,6.22)      (0.04,0.61)    (0.07,0.69)    (0.01,0.19)    (0.05,1.03)    (0.03,0.37)    (0.18,2.46)      (0.44,4.88)      (0.05,0.70)     (0.01,0.03)   (0.15,1.02)     (0.18,1.17)
  CSA 2.5 mg    3.22            7.11             --             4.98             1.16           1.43           0.34           1.74           0.78           4.42             9.89             1.29            0.09          2.88            3.32
                (0.74,12.82)    (0.99,36.73)                    (1.75,13.54)     (0.13,7.39)    (0.24,7.30)    (0.04,2.07)    (0.23,8.30)    (0.10,4.39)    (0.85,20.65)     (2.18,39.43)     (0.37,3.97)     (0.01,0.35)   (0.46,12.78)    (0.51,14.83)
  CSA 5 mg      0.67            1.49             0.20           --               0.24           0.29           0.07           0.36           0.16           0.91             2.06             0.44            0.02          0.60            0.69
                (0.12,2.95)     (0.16,8.29)      (0.07,0.57)                     (0.02,1.67)    (0.04,1.67)    (0.01,0.47)    (0.03,1.95)    (0.01,1.02)    (0.12,4.84)      (0.30,9.18)      (0.14,1.57)     (0.00,0.08)   (0.07,2.96)     (0.08,3.38)
  Etanercept    2.73            6.15             0.86           4.15             --             1.23           0.28           1.46           0.66           3.85             8.51             1.11            0.07          2.48            2.85
  100 mg QW     (0.65,17.41)    (1.63,23.99)     (0.14,7.79)    (0.60,51.05)                    (0.35,5.34)    (0.08,1.07)    (0.62,3.62)    (0.22,2.09)    (0.86,19.38)     (2.13,40.28)     (0.26,5.97)     (0.02,0.24)   (0.80,7.72)     (0.91,8.85)
  Etanercept    2.32            5.07             0.70           3.40             0.82           --             0.28           1.43           0.55           3.19             7.09             0.90            0.06          2.02            2.32
  25 mg BIW     (0.63,8.84)     (1.44,14.66)     (0.14,4.22)    (0.60,27.08)     (0.19,2.89)                   (0.06,1.16)    (0.39,4.95)    (0.15,1.65)    (0.77,11.49)     (1.92,22.79)     (0.24,3.19)     (0.02,0.13)   (0.72,4.84)     (0.81,5.63)
  Etanercept    9.73            22.27            2.97           14.40            3.55           3.60           --             5.25           2.37           13.91            29.78            3.86            0.26          8.81            10.19
  25 mg QW      (2.22,58.96)    (5.23,85.70)     (0.48,27.13)   (2.13,179.59)    (0.94,12.49)   (0.86,16.14)                  (1.99,13.30)   (0.73,7.27)    (2.92,65.68)     (7.31,139.88)    (0.91,20.80)    (0.05,1.37)   (2.69,28.14)    (3.01,31.84)
  Etanercept    1.83            4.29             0.58           2.75             0.69           0.70           0.19           --             0.45           2.65             5.70             0.74            0.05          1.68            1.85
  50 mg BIW     (0.60,9.27)     (0.97,18.85)     (0.12,4.32)    (0.51,30.05)     (0.28,1.62)    (0.20,2.55)    (0.08,0.50)                   (0.23,0.89)    (0.76,10.26)     (1.94,21.09)     (0.24,3.10)     (0.01,0.21)   (0.81,3.59)     (0.48,7.46)
  Etanercept    4.05            9.31             1.28           6.17             1.51           1.81           0.42           2.21           --             5.75             12.64            1.65            0.11          3.75            4.28
  50 mg QW      (1.07,23.01)    (2.69,31.37)     (0.23,10.48)   (0.98,71.10)     (0.48,4.51)    (0.61,6.84)    (0.14,1.36)    (1.12,4.33)                   (1.43,27.06)     (3.64,54.57)     (0.44,7.93)     (0.04,0.30)   (1.36,9.87)     (1.56,11.25)
  Infliximab    0.72            1.61             0.23           1.10             0.26           0.31           0.07           0.38           0.17           --               2.18             0.29            0.02          0.65            0.74
  3 mg          (0.21,2.67)     (0.41,5.67)      (0.05,1.17)    (0.21,8.04)      (0.05,1.16)    (0.09,1.30)    (0.02,0.34)    (0.10,1.31)    (0.04,0.70)                     (1.10,4.75)      (0.10,0.87)     (0.01,0.05)   (0.19,1.97)     (0.21,2.29)
  Infliximab    0.33            0.73             0.10           0.49             0.12           0.14           0.03           0.18           0.08           0.46             --               0.13            0.01          0.29            0.34
  5 mg          (0.11,1.01)     (0.20,2.28)      (0.03,0.46)    (0.11,3.34)      (0.02,0.47)    (0.04,0.52)    (0.01,0.14)    (0.05,0.51)    (0.02,0.27)    (0.21,0.91)                       (0.06,0.31)     (0.00,0.02)   (0.09,0.78)     (0.11,0.90)
  MTX           2.55            5.57             0.78           2.25             0.90           1.11           0.26           1.35           0.61           3.49             7.69             --              0.05          2.26            2.59
                (0.99,6.18)     (1.42,18.42)     (0.25,2.68)    (0.64,6.94)      (0.17,3.89)    (0.31,4.20)    (0.05,1.10)    (0.32,4.20)    (0.13,2.26)    (1.15,9.75)      (3.28,17.36)                     (0.00,0.15)   (0.63,6.30)     (0.72,7.30)
  Placebo       30.93           84.29            11.71          55.90            13.57          16.61          3.83           20.24          9.10           53.49            117.81           19.04           --            33.57           38.81
                (16.26,58.97)   (37.74,187.34)   (2.86,69.09)   (12.23,452.23)   (4.22,41.45)   (7.77,43.27)   (0.73,18.81)   (4.73,75.32)   (3.34,24.47)   (19.24,158.08)   (54.46,286.70)   (6.83,242.20)                 (20.28,55.73)   (22.22,64.79)
  Ustekinumab   1.09            2.48             0.35           1.66             0.40           0.49           0.11           0.60           0.27           1.54             3.43             0.44            0.03          --              1.19
  45 mg         (0.39,4.55)     (0.98,6.47)      (0.08,2.18)    (0.34,14.71)     (0.13,1.26)    (0.21,1.38)    (0.04,0.37)    (0.28,1.23)    (0.10,0.74)    (0.51,5.35)      (1.28,10.57)     (0.16,1.58)     (0.02,0.05)                   (0.34,4.29)
  Ustekinumab   0.96            2.17             0.30           1.44             0.35           0.43           0.10           0.54           0.23           1.36             2.97             0.39            0.03          0.84            --
  90 mg         (0.34,3.97)     (0.85,5.68)      (0.07,1.95)    (0.30,13.07)     (0.11,1.10)    (0.18,1.23)    (0.03,0.33)    (0.13,2.07)    (0.09,0.64)    (0.44,4.82)      (1.11,9.46)      (0.14,1.40)     (0.02,0.05)   (0.23,2.94)     

PASI, Psoriasis Area and Severity Index; MTX, methotrexate; CSA, cyclosporin A; BIW, twice weekly; QW, once weekly.

###### 

Network meta-analysis of PASI 50 response rate between drugs for treating psoriasis.

                                               Etanercept     Infliximab                                    Ustekinumab                                                                  
  ------------- -------------- --------------- -------------- -------------- -------------- --------------- -------------- ---------------- -------------- ------------- --------------- ---------------
  Adalimumab    --             1.12            0.59           0.41           0.17           0.79            0.61           1.75             0.29           0.04          1.40            1.85
                               (0.22,7.80)     (0.12,2.68)    (0.11,1.38)    (0.04,0.65)    (0.21,2.82)     (0.18,2.20)    (0.59,5.64)      (0.12,0.72)    (0.01,0.11)   (0.36,4.25)     (0.47,5.75)
  CSA 5 mg      0.89           --              0.51           0.35           0.15           0.67            0.55           1.57             0.26           0.03          1.21            1.59
                (0.13,4.63)                    (0.06,3.81)    (0.05,2.02)    (0.02,0.94)    (0.10,4.15)     (0.08,3.08)    (0.27,8.03)      (0.05,1.01)    (0.00,0.13)   (0.17,6.72)     (0.22,8.98)
  Etanercept    1.71           1.97            --             0.70           0.29           1.33            1.06           3.04             0.50           0.05          2.36            3.14
  100 mg QW     (0.37,8.01)    (0.26,16.88)                   (0.22,2.31)    (0.08,1.10)    (0.58,3.37)     (0.27,4.26)    (0.85,11.44)     (0.12,2.03)    (0.02,0.15)   (0.70,7.67)     (0.90,10.08)
  Etanercept    2.44           2.83            1.43           --             0.42           1.88            1.54           4.35             0.71           0.08          3.36            4.51
  25 mg BIW     (0.72,9.29)    (0.49,18.45)    (0.43,4.52)                   (0.19,0.88)    (0.60,7.67)     (0.56,3.92)    (1.84,10.84)     (0.25,1.96)    (0.04,0.12)   (1.56,6.53)     (1.92,8.78)
  Etanercept    5.82           6.76            3.47           2.38           --             4.48            3.67           10.43            1.70           0.18          8.06            10.77
  25 mg QW      (1.55,24.11)   (1.06,50.81)    (0.91,12.67)   (1.14,5.26)                   (1.25,21.93)    (1.18,11.20)   (3.89,31.14)     (0.52,5.66)    (0.08,0.39)   (3.09,19.57)    (3.84,25.87)
  Etanercept    1.27           1.48            0.75           0.53           0.22           --              0.80           2.28             0.37           0.04          1.76            2.36
  50 mg BIW     (0.36,4.71)    (0.24,9.91)     (0.30,1.74)    (0.13,1.66)    (0.05,0.80)                    (0.26,2.15)    (0.88,5.66)      (0.12,1.08)    (0.02,0.07)   (0.72,3.61)     (0.90,4.92)
  Infliximab    1.63           1.83            0.94           0.65           0.27           1.25            --             2.87             0.47           0.05          2.18            2.91
  3 mg          (0.45,5.59)    (0.33,11.99)    (0.23,3.72)    (0.26,1.79)    (0.09,0.85)    (0.47,3.79)                    (1.49,5.97)      (0.17,1.18)    (0.02,0.11)   (0.79,5.79)     (1.00,7.85)
  Infliximab    0.57           0.64            0.33           0.23           0.10           0.44            0.35           --               0.16           0.01          0.77            1.01
  5 mg          (0.18,1.69)    (0.12,3.76)     (0.09,1.18)    (0.09,0.54)    (0.03,0.26)    (0.18,1.14)     (0.17,0.67)                     (0.07,0.32)    (0.01,0.03)   (0.30,1.81)     (0.38,2.38)
  MTX           3.47           3.90            2.01           1.41           0.59           2.68            2.13           6.07             --             0.16          4.73            6.32
                (1.40,8.48)    (0.99,20.60)    (0.49,8.47)    (0.51,4.03)    (0.18,1.93)    (0.92,8.59)     (0.85,5.91)    (3.09,14.56)                    (0.07,0.42)   (1.65,12.90)    (2.13,17.45)
  Placebo       25.54          37.03           19.15          13.18          5.56           25.18           20.48          75.64            6.11           --            44.24           59.44
                (8.86,70.76)   (7.41,242.17)   (6.52,56.34)   (8.43,23.22)   (2.58,12.19)   (14.53,50.34)   (8.87,47.46)   (37.84,166.80)   (2.36,14.83)                 (26.51,73.29)   (32.83,99.32)
  Ustekinumab   0.72           0.83            0.42           0.30           0.12           0.57            0.46           1.30             0.21           0.02          --              1.34
  45 mg         (0.24,2.79)    (0.15,5.84)     (0.13,1.43)    (0.15,0.64)    (0.05,0.32)    (0.28,1.38)     (0.17,1.26)    (0.55,3.33)      (0.08,0.61)    (0.01,0.04)                   (0.77,2.22)
  Ustekinumab   0.54           0.63            0.32           0.22           0.09           0.42            0.34           0.99             0.16           0.02          0.75            --
  90 mg         (0.17,2.12)    (0.11,4.46)     (0.10,1.12)    (0.11,0.52)    (0.04,0.26)    (0.20,1.11)     (0.13,1.00)    (0.42,2.64)      (0.06,0.47)    (0.01,0.03)   (0.45,1.30)     

PASI, Psoriasis Area and Severity Index; MTX, methotrexate; CSA, cyclosporin A; BIW, twice weekly; QW, once weekly.

###### 

Network meta-analysis of PASI 90 response rate between different drugs used to treat psoriasis.

                                                                             Etanercept         Infliximab                                                 Ustekinumab                                                                   
  ------------- ------------------- -------------------- ------------------- ------------------ ------------------ ------------------- ------------------- ------------------- ------------------ ------------------ ------------------- -------------------
  Adalimumab    --                  3.84 (1.16,11.56)    0.66 (0.11,4.09)    0.33 (0.12,1.04)   0.08 (0.02,0.33)   0.70 (0.28,1.85)    1.03 (0.35,3.58)    1.50 (0.58,4.27)    0.19 (0.08,0.44)   0.03 (0.01,0.06)   1.60 (0.63,4.31)    1.71 (0.64,4.60)
  Briakinumab   0.26 (0.09,0.86)    --                   0.17 (0.03,1.36)    0.09 (0.04,0.25)   0.02 (0.00,0.08)   0.18 (0.10,0.38)    0.27 (0.08,1.14)    0.39 (0.13,1.44)    0.05 (0.02,0.16)   0.01 (0.00,0.02)   0.42 (0.18,1.11)    0.45 (0.19,1.15)
  CSA 5 mg      1.51 (0.24,9.19)    5.76 (0.73,39.77)    --                  0.50 (0.07,3.26)   0.12 (0.01,0.91)   1.09 (0.16,6.79)    1.58 (0.25,9.60)    2.27 (0.38,12.56)   0.28 (0.06,1.23)   0.05 (0.01,0.27)   2.48 (0.34,15.66)   2.65 (0.37,17.51)
  Etanercept    3.03                11.47                2.00                --                 0.23               2.12                3.13                4.52                0.56               0.09               4.79                5.20
  25 mg BIW     (0.96,8.27)         (4.06,27.25)         (0.31,14.20)                           (0.06,0.74)        (1.04,4.02)         (0.90,11.65)        (1.51,13.74)        (0.17,1.64)        (0.04,0.18)        (1.92,11.25)        (2.01,11.76)
  Etanercept    13.17               50.02                8.64                4.34               --                 9.08                13.87               19.96               2.54               0.39               20.56               22.36
  25 mg QW      (3.06,58.45)        (12.01,212.82)       (1.10,79.40)        (1.36,17.31)                          (2.86,33.94)        (2.99,74.25)        (4.65,97.31)        (0.53,10.70)       (0.11,1.48)        (5.65,85.77)        (5.77,93.02)
  Etanercept    1.42                5.43                 0.92                0.47               0.11               --                  1.46                2.12                0.27               0.04               2.27                2.46
  50 mg BIW     (0.54,3.57)         (2.62,10.08)         (0.15,6.31)         (0.25,0.96)        (0.03,0.35)                            (0.51,5.15)         (0.85,6.07)         (0.10,0.70)        (0.02,0.07)        (1.21,4.37)         (1.25,4.56)
  Infliximab    0.97                3.71                 0.63                0.32               0.07               0.68                --                  1.45                0.18               0.03               1.55                1.68 (0.45,4.92)
  3 mg          (0.28,2.87)         (0.88,12.40)         (0.10,4.03)         (0.09,1.11)        (0.01,0.33)        (0.19,1.97)                             (0.74,2.71)         (0.06,0.43)        (0.01,0.07)        (0.43,4.64)         
  Infliximab    0.67                2.56                 0.44                0.22               0.05               0.47                0.69                --                  0.13               0.02               1.07                1.16
  5 mg          (0.23,1.71)         (0.70,7.58)          (0.08,2.63)         (0.07,0.66)        (0.01,0.21)        (0.16,1.18)         (0.37,1.36)                             (0.05,0.25)        (0.01,0.04)        (0.36,2.79)         (0.37,3.04)
  MTX           5.31 (2.25,13.20)   20.30 (6.20,62.98)   3.55 (0.81,17.74)   1.79 (0.61,5.77)   0.39 (0.09,1.89)   3.77 (1.43,10.05)   5.50 (2.32,16.93)   7.96 (3.98,19.45)   --                 0.16 (0.07,0.34)   8.58 (3.19,23.75)   9.20 (3.33,25.36)
  Placebo       33.59               130.12               22.14               11.08              2.57               23.55               35.13               51.03               6.34               --                 53.93               58.50
                (16.46,70.67)       (52.97,292.89)       (3.73,137.96)       (5.43,26.18)       (0.67,8.86)        (13.83,43.77)       (13.99,103.31)      (23.99,121.47)      (2.92,13.46)                          (29.01,100.56)      (29.98,110.26)
  Ustekinumab   0.63                2.41                 0.40                0.21               0.05               0.44                0.65                0.93                0.12               0.02               --                  1.09
  45 mg         (0.23,1.58)         (0.90,5.51)          (0.06,2.91)         (0.09,0.52)        (0.01,0.18)        (0.23,0.82)         (0.22,2.31)         (0.36,2.81)         (0.04,0.31)        (0.01,0.03)                            (0.66,1.67)
  Ustekinumab   0.58                2.21                 0.38                0.19               0.04               0.41                0.60                0.86                0.11               0.02               0.92                --
  90 mg         (0.22,1.57)         (0.87,5.33)          (0.06,2.69)         (0.09,0.50)        (0.01,0.17)        (0.22,0.80)         (0.20,2.24)         (0.33,2.74)         (0.04,0.30)        (0.01,0.03)        (0.60,1.52)         

PASI, Psoriasis Area and Severity Index; MTX, methotrexate; CSA, cyclosporin A; BIW, twice weekly; QW, once weekly.

###### 

Rank analysis of PASI 90 response rate of the drugs for treating psoriasis.

  Treatment              Rank 1   Rank 2   Rank 3   Rank 4   Rank 5   Rank 6   Rank 7   Rank 8   Rank 9   Rank 10   Rank 11   Rank 12
  ---------------------- -------- -------- -------- -------- -------- -------- -------- -------- -------- --------- --------- ---------
  Adalimumab             0.01     0.03     0.05     0.13     0.21     0.28     0.22     0.07     0.01     0.00      0.00      0.00
  Briakinumab            0.86     0.08     0.03     0.02     0.01     0.00     0.00     0.00     0.00     0.00      0.00      0.00
  CSA 5 mg               0.03     0.07     0.04     0.06     0.07     0.09     0.14     0.25     0.17     0.05      0.01      0.00
  Etanercept 25 mg BIW   0.00     0.00     0.00     0.00     0.00     0.01     0.03     0.23     0.59     0.14      0.00      0.00
  Etanercept 25 mg QW    0.00     0.00     0.00     0.00     0.00     0.00     0.00     0.00     0.02     0.09      0.81      0.07
  Etanercept 50 mg BIW   0.00     0.00     0.00     0.03     0.07     0.18     0.35     0.35     0.01     0.00      0.00      0.00
  Infliximab 3 mg        0.02     0.04     0.09     0.09     0.22     0.24     0.20     0.09     0.02     0.00      0.00      0.00
  Infliximab 5 mg        0.05     0.23     0.16     0.30     0.18     0.08     0.02     0.00     0.00     0.00      0.00      0.00
  MTX                    0.00     0.00     0.00     0.00     0.00     0.00     0.00     0.01     0.18     0.70      0.10      0.00
  Placebo                0.00     0.00     0.00     0.00     0.00     0.00     0.00     0.00     0.00     0.00      0.07      0.93
  Ustekinumab 45 mg      0.01     0.18     0.35     0.21     0.14     0.08     0.02     0.00     0.00     0.00      0.00      0.00
  Ustekinumab 90 mg      0.02     0.37     0.28     0.16     0.10     0.05     0.02     0.00     0.00     0.00      0.00      0.00

Rank 1 indicates the best rating, while Rank 12 indicates the worst rating. PASI, Psoriasis Area and Severity Index; MTX, methotrexate; CSA, cyclosporin A; BIW, twice weekly; QW, once weekly.
